Page 34 - TD-4-1

Tumor Discovery Immunohistochemistry profiling of ovarian cysts

doi: 10.1038/s41416-019-0401-1 tumor patients. PLoS One. 2020;15(10):e0240418.
88. Xu HL, Gong TT, Liu FH, et al. Artificial intelligence doi: 10.1371/journal.pone.0240418
performance in image-based ovarian cancer identification:
A systematic review and meta-analysis. EClinicalMedicine. 91. Wang Y, Coleman RL. The future of ovarian cancer
2022;53:101662. screening. J Clin Oncol. 2021;39(23):2639-2646.
doi: 10.1016/j.eclinm.2022.101662 doi: 10.1200/JCO.21.00048
89. Brule AJ, Buist MR, Massuger LF, Rotteveel J, Vergote I, 92. Holst S, Heeren RM. New horizons in ovarian cancer
Trimbos JB. Comparison of CA125, HE4, and a multimodal diagnostics: YKL-40 and mesothelin as potential markers.
immunocytochemical assay for ovarian cancer risk Nat Rev Clin Oncol. 2020;17(10):615-627.
stratification. Gynecol Oncol. 2018;151(2):353-360. doi: 10.1038/s41571-020-0379-3
doi: 10.1016/j.ygyno.2018.09.012 93. Dijmărescu AL, Gheorman V, Manolea MM, et al. Serological
90. Leandersson P, Åkesson A, Hedenfalk I, Malander S, and immunohistochemical biomarkers for discrimination
Borgfeldt C. A multiplex biomarker assay improves the between benign and malignant ovarian tumors. Rom J
diagnostic performance of HE4 and CA125 in ovarian Morphol Embryol. 2019;60(4):1163-1174.

Volume 4 Issue 1 (2025) 26 doi: 10.36922/td.5369